<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000743</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 201</org_study_id>
    <secondary_id>11177</secondary_id>
    <nct_id>NCT00000743</nct_id>
  </id_info>
  <brief_title>A Phase I, Dose-Escalating Safety and Tolerance Study of sCD4-PE40 in HIV-Infected Persons</brief_title>
  <official_title>A Phase I, Dose-Escalating Safety and Tolerance Study of sCD4-PE40 in HIV-Infected Persons</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Upjohn</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To determine the safety and tolerance of alvircept sudotox (sCD4-PE40) given at various&#xD;
      dosing intervals and concentrations. To determine whether frequent dosing alters&#xD;
      immunogenicity or toxicity. To obtain preliminary data to ascertain whether sCD4-PE40 has&#xD;
      activity against HIV in human subjects. To determine whether there is any additive toxicity&#xD;
      with combined use of sCD4-PE40 and zidovudine (AZT).&#xD;
&#xD;
      There is some evidence that AZT and sCD4-PE40, an experimental drug with anti-HIV activity&#xD;
      previously demonstrated in vitro, may produce increased benefit when used in combination in&#xD;
      HIV-infected patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is some evidence that AZT and sCD4-PE40, an experimental drug with anti-HIV activity&#xD;
      previously demonstrated in vitro, may produce increased benefit when used in combination in&#xD;
      HIV-infected patients.&#xD;
&#xD;
      Cohorts of six patients each receive escalating doses of sCD4-PE40 in a single IV weekly dose&#xD;
      for 8 weeks. All six patients at a given dose must complete 2 weeks of therapy without&#xD;
      dose-limiting toxicity before dose escalation in subsequent patient cohorts may occur. The&#xD;
      MTD is defined as the dose of sCD4-PE40 immediately below that at which two or more of six&#xD;
      patients experience grade 3 or higher toxicity or one or more of six patients experience&#xD;
      grade 4 toxicity. After the MTD for the once-weekly schedule is reached, subsequent cohorts&#xD;
      receive escalated doses of sCD4-PE40 on a 5x weekly schedule for approximately 4 weeks, in an&#xD;
      attempt to establish the MTD for that schedule. When an MTD has been determined for the 5x&#xD;
      weekly schedule, and if antiretroviral activity is observed, six additional patients receive&#xD;
      this dose combined with AZT for 4 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">May 1995</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>64</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alvircept sudotox</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  PCP prophylaxis with aerosolized pentamidine, trimethoprim / sulfamethoxazole, or&#xD;
             dapsone.&#xD;
&#xD;
          -  Clotrimazole troches or nystatin oral suspension for oral candidiasis.&#xD;
&#xD;
          -  Acyclovir (up to 1000 mg/day for 10 days) for herpes lesions.&#xD;
&#xD;
          -  Erythropoietin.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Documented HIV infection by ELISA confirmed by a second method. If a prior diagnosis&#xD;
             of AIDS has not been established by CDC criteria, a confirmatory test is required.&#xD;
&#xD;
          -  CD4 count = or &lt; 300 cells/mm3 within 4 weeks prior to study entry.&#xD;
&#xD;
          -  Positive p24 antigen.&#xD;
&#xD;
        Patients entering the AZT portion of the study only:&#xD;
&#xD;
          -  Must be AZT naive or have had less than 2 months of AZT therapy.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms and conditions are excluded:&#xD;
&#xD;
          -  Hemophilia.&#xD;
&#xD;
          -  Acute medical problems (including active opportunistic infections such as active&#xD;
             cryptococcosis, Pneumocystis carinii, herpes zoster, histoplasmosis, or CMV or&#xD;
             nonopportunistic diseases including liver disease, renal disease, or orthostatic&#xD;
             hypotension) at time of study entry.&#xD;
&#xD;
          -  Active pulmonary disease.&#xD;
&#xD;
          -  Chronic active hepatitis B surface antigenemia or unstable hepatitis C.&#xD;
&#xD;
          -  Current diagnosis of malignancy for which systemic therapy would be required during&#xD;
             the study.&#xD;
&#xD;
          -  Inadequate intravenous access.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Hepatotoxic agents.&#xD;
&#xD;
          -  Other antiretroviral or immunomodulator agents (including but not limited to AZT, ddI,&#xD;
             ddC, interferon, and steroids).&#xD;
&#xD;
          -  Other investigational drugs.&#xD;
&#xD;
          -  Systemic therapy for malignancy.&#xD;
&#xD;
          -  G-CSF and GM-CSF.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Other antiretroviral or immunomodulator agents (including but not limited to AZT, ddI,&#xD;
             ddC, interferon, and steroids) within 4 weeks prior to study entry.&#xD;
&#xD;
          -  Ribavirin within 90 days prior to study entry.&#xD;
&#xD;
          -  Cytotoxic chemotherapy within one month prior to study entry.&#xD;
&#xD;
          -  Prior soluble CD4 or CD4-Ig.&#xD;
&#xD;
        Excluded in patients entering the AZT portion of the study:&#xD;
&#xD;
          -  More than 2 months of prior AZT therapy.&#xD;
&#xD;
        Current active alcoholism or active substance abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>van der Horst C</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>UCLA CARE Center CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Med. Ctr. - Charity Hosp. of New Orleans, ACTU</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>701122699</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Adult AIDS CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unc Aids Crs</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>275997215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Alston B, Mitsuyasu R, Lertora J, Flexner C, Timpone J, van der Horst C. Phase I study of sCd4-PE40 in HIV infected persons: (ACTG 201). Int Conf AIDS. 1993 Jun 6-11;9(1):498 (abstract no PO-B29-2178)</citation>
  </reference>
  <reference>
    <citation>Fiscus S, et al. Safety and efficacy of soluble CD4-pseudomonas exotoxin 40 in HIV infected individuals (ACTG 201). Natl Conf Hum Retroviruses Relat Infect (2nd). 1995 Jan 29-Feb 2:70</citation>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recombinant Proteins</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Antigens, CD4</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

